levetiracetam
AssetAlso AGB101, Keppra XR, Levetiracetam (LEV), Keppra XR (Levetiracetam XR)
Binds synaptic vesicle protein SV2A to modulate neurotransmitter release and reduce seizures.
- Stage
- Approved
- Modality
- Small molecule
- Target
- SV2A
- 20
- Indications
- 160
- Trials
- 5
- Developers
Indications
20Epilepsy
Approved, accessdata.fda.gov, 7 Oct 2026
Epilepsy, Idiopathic Generalized
Approved, accessdata.fda.gov, 7 Oct 2026
Generalized tonic clonic seizure
Approved, accessdata.fda.gov, 7 Oct 2026
17 more
In the full profile
- Targets and what it contains1
- Owner and partners5
- Trials160
- Evidence for its targets2
- Competitors11
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 10 Oct 2026, 53 sources